Physician profile
Susan Cox
NPI 1811985724
$5,164.33
in general payments reported to CMS, 2019-2025
28 companies · $579 in 2025
The $579 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $855 · 2020: $371 · 2021: $919 · 2022: $877 · 2023: $816 · 2024: $748 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,142.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $838.84 | 2019-2025 | Skyrizi |
| Pfizer INC. | $594.73 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $586.60 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $558.83 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $463.74 | 2020-2025 | |
| Leo Pharma INC. | $315.11 | 2019-2025 | Anzupgo |
| Janssen Biotech, INC. | $278.71 | 2019-2025 | Tremfya, Simponi, Stelara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $184.91 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Lilly USA, LLC | $157.49 | 2019-2023 | Olumiant, Taltz |
| Allergan, INC. | $144.36 | 2019-2022 | |
| Galderma Laboratories, L.P. | $133.37 | 2019-2025 | Aklief |
| Incyte Corporation | $128.76 | 2022-2024 | Opzelura |
| Sun Pharmaceutical Industries INC. | $123.34 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $83.66 | 2019-2025 | |
| Boston Scientific Corporation | $82.48 | 2023-2025 | Wavewriter Alpha Prime 16 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.18 | 2022-2023 | Spevigo |
| Amgen INC. | $58.59 | 2023-2024 | Otezla |
| Dermavant Sciences, INC. | $56.71 | 2024 | Vtama |
| Prugen, INC. Pharmaceuticals | $49.02 | 2019 | |
| Arcutis Biotherapeutics, INC. | $47.57 | 2023 | |
| Almirall LLC | $41.10 | 2019-2022 | |
| Journey Medical Corporation | $40.04 | 2019-2025 | |
| Dermira, INC. | $24.65 | 2020 | |
| Verrica Pharmaceuticals INC. | $22.57 | 2024 | Ycanth |
| Organon LLC | $22.44 | 2025 | Vtama |
| Sandoz INC. | $19.26 | 2020 | |
| Biofrontera INC. | $17.39 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Medimetriks Pharmaceuticals, INC. | $13.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.